Asceneuron Raises $100 Million Series C Funding
Asceneuron SA, a clinical-stage biotech company focused on developing small molecules that target tau protein aggregation in neurodegenerative diseases, has ...
Asceneuron SA, a clinical-stage biotech company focused on developing small molecules that target tau protein aggregation in neurodegenerative diseases, has ...
Researchers have pinpointed 15 lifestyle and health risk factors associated with a rare form of dementia that impacts individuals under ...
To boost the computing power of artificial intelligence (AI), researchers have combined run-of-the-mill machine learning with a sophisticated 3D model ...
At IMPAAKT, we combine the power of mass surveys and advanced business journalism tools to create a comprehensive understanding of the dynamic business landscape.
Disclaimer: The information broadcasted by IMPAAKT MAGAZINE is the exclusive property of SOCNITY MEDIA. Unauthorized use of content is prohibited, and legal action may be taken against violators. We make no guarantees about content accuracy or completeness. For any queries, please reach out to info@impaakt.co.
Impaakt.co Copyright (c) 2025 by Socnity Media Group. All Rights Reserved.